KM

Karen M. Murphy

Geisinger Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Thierry Olivry

North Carolina State University

Hilary A. Jackson

Stepping Hill Hospital

Christine Rivierre

North Carolina State University

Stanley M. Dunston

North Carolina State University

Diane L. Gill

University of North Carolina at Greensboro

Cara C. Hammond

University of North Carolina at Greensboro

Yu‐Kai Chang

National Taiwan Normal University

Enid A. Rodriguez

University of North Carolina at Greensboro

Kathryn M. Speed

University of North Carolina at Greensboro

Mark Hennessey

University Hospital Galway

Cooperative Institutions

North Carolina State University

University of North Carolina at Greensboro

North Central State College

American Medical Association

National Heart Foundation of Australia

University of California, Davis

Temple Street Children's University Hospital

University of Ulster

University of North Carolina at Chapel Hill

Boston Children's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone‐controlled trial*

Veterinary Dermatology (2002)

Thierry Olivry Christine Rivierre Hilary A. Jackson Karen M. Murphy Gigi Davidson

Abstract During the last decade, oral cyclosporin (CsA) has proven to be effective, in randomized controlled trials, for the treatment of atopic dermatitis (AD) in human patients. The purpose of this blinded randomized controlled trial was to test the hypothesis that CsA was successful in reducing the gravity of clinical signs of AD in dogs. Thirty dogs with nonseasonal AD were randomly allocated to receive an oral solution of either NEORAL CsA (5 mg kg −1 ) or prednisolone (0.5 mg kg −1 ) once daily for 6 weeks. Before, and 3 and 6 weeks after therapy, skin lesions were graded by clinicians using the Canine AD Extent and Severity Index (CADESI). Pruritus was assessed by the owners using a visual analog scale (PVAS). In both groups, CADESI and PVAS values were significantly lower at 6 weeks post treatment than before the initiation of therapy (Friedman test, P < 0.0004). The percentage reductions in CADESI and PVAS values from baseline were not statistically different between groups (Mann–Whitney test, P > 0.3). In this experiment, the tolerability and safety of oral CsA and prednisolone appeared similar. One‐fifth of dogs given oral CsA occasionally developed diarrhoea or soft stools. One dog that was given CsA developed a generalized papillomatous skin eruption during the second half of the trial. Our study provides randomized controlled trial evidence that CsA reduces the severity of clinical signs in dogs with nonseasonal AD. Moreover, the anti‐allergic efficacy of CsA appears comparable with that of prednisolone. We propose that oral CsA should be considered as a valuable alternative to glucocorticoid therapy in dogs with AD.

Tolerability

Prednisolone

10.1046/j.1365-3164.2002.00283.x

Cite

Citations (141)

Evaluation of a point‐of‐care immunodot assay for predicting results of allergen‐specific intradermal and immunoglobulin E serological tests

Veterinary Dermatology (2005)

Thierry Olivry Hilary A. Jackson Karen M. Murphy Kathy C. Tater Malcolm C. Roberts

Abstract Immunotherapy to prevent recurrence of clinical signs of atopic dermatitis (AD) is based on intradermal or serological tests that assist in identifying allergen‐specific immunoglobulin E hypersensitivities. Unfortunately, the results of such tests can be negatively influenced by several factors, which include the age of the patients, the season of testing and the administration of anti‐allergic drugs. Screening to predict when these expensive tests will be useful would benefit owners of dogs with AD. The objectives of this study were to determine whether a point‐of‐care allergen‐specific immunodot assay (Allercept E‐Screen©, Heska Corp., Ft Collins, CO, USA) could predict results of either intradermal or Allercept© full panel serological tests in atopic dogs. Thirty dogs living in the south‐eastern USA were diagnosed with AD in accordance with current standards. Allergen‐specific intradermal, serological and E‐Screen© tests were performed in all subjects. For flea, house dust mite and pollen allergens altogether, results of the E‐Screen© assay agreed with those of intradermal and serological tests in 26/30 dogs (87%) and 25/30 dogs (83%), respectively. In this group of dogs, the probabilities of obtaining intradermal or serological tests positive for these allergens were 70 and 67%, respectively. If either skin or serum tests were performed only in dogs with positive E‐Screen© tests, the probability of obtaining positive results would be increased from 70 to 95% and from 67 to 90%, respectively. In this population of dogs with AD, results of the E‐Screen© point‐of‐care immunodot assay was found to often agree with those of allergen‐specific intradermal or Allercept© tests for selected allergen groups.

Point-of-Care Testing

10.1111/j.1365-3164.2005.00442.x

Cite

Citations (10)

Bullous systemic lupus erythematosus (type I) in a dog

Veterinary Record (1999)

Thierry Olivry Karine C.M. Savary Karen M. Murphy Stanley M. Dunston M. Chen

In human patients with systemic lupus erythematosus, cutaneous subepidermal blistering can occur because of the production of antibodies specific for basement membrane antigens. This condition is referred to as bullous systemic lupus erythematosus (BSLE). A dog was diagnosed with BSLE because it because of the production of antibodies specific for basement membrane antigens. This condition is referred to as bullous systemic lupus erythematosus (BSLE). A dog was diagnosed with BSLE because it fulfilled the following criteria: (i) a diagnosis of systemic lupus erythematosus by standard methods; (ii) an acquired, vesicular, erosive and ulcerative eruption; (iii) microscopical subepidermal vesicles with neutrophil‐predominant inflammation at the dermo‐epidermal junction; (iv) deposition of IgG at the epidermal basement membrane zone; and (v) circulating IgG autoantibodies against type VIl collagen. Anti‐collagen Vil type l‐BSLE therefore needs to be considered as a possible differential diagnosis for canine autoimmune subepidermal blistering diseases.

10.1136/vr.145.6.165

Cite

Citations (26)

Nonprimary Care Physicians' Views on Office-Based Quality Incentive and Improvement Programs

American Journal of Medical Quality (2008)

Karen M. Murphy David B. Nash

The current pay-for-performance movement in health care has continued to evolve despite the absence of input from physicians and empirical evidence of its effectiveness. The majority of existing quality incentive programs related to physician services is limited to primary care physicians. There is an increasing movement among payers to broaden pay for performance to include nonprimary care physicians. This article reports the results of a survey of nonprimary care physicians' views on office-based quality incentive and improvement programs. Data were collected from surveys completed by nonprimary care physicians practicing cardiology, hematology, oncology, obstetrics and gynecology, orthopedic surgery, and urology. Findings indicate that nonprimary care physicians recognize some value in office-based quality incentive and improvement programs. Specialty societies played a significant role in influencing physicians' views on office-based quality improvements. Physicians indicated support for incentive designs that included infrastructure grants to implement improvements in their office such as an electronic medical record. (Am J Med Qual 2008;23:427-439)

Specialty

Incentive program

Patient Care

Pay for Performance

10.1177/1062860608324557

Cite

Citations (11)

A Path to Sustain Rural Hospitals

Karen M. Murphy Lauren S. Hughes Patrick H. Conway

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal

10.1001/jama.2018.2967

Cite

Citations (22)

Quality of Life Assessment in Physical Activity and Health Promotion

Medicine & Science in Sports & Exercise (2006)

Diane L. Gill Yu‐Kai Chang Karen M. Murphy Kathryn M. Holder Jennifer L. Etnier

Enhanced quality of life (QoL) is a target outcome for physical activity and health promotion programs, but QoL measures are as varied as the programs, and leading researchers note major shortcomings in our conceptual models and measures. QoL measures range from integrative subjective well-being (e.g., Diener's SWL scale) to aggregate measures of separate components such as physical function, social, cognitive and spiritual well-being (e.g., SF-36), and even extend to indirect measures of related constructs (e.g., depression). Conceptually-based, psychometrically-sound QoL assessment is needed to advance research, and to effectively evaluate community based health promotion programs. PURPOSE: to conduct a systematic review of recent research on physical activity and QoL as a preliminary step in the development of reliable, valid and relevant QoL measures for community-based physical activity programs. METHODS: We targeted research articles in health psychology/behavioral medicine, health promotion, and exercise and sport science from 2001–2005 to identify the current models and measures. PsycINFO and EBSCO searches were used to locate articles with Physical Activity or Exercise and QoL. RESULTS: From over 300 citations, 60 were studies on physical activity/exercise and QoL. Those were approximately equally divided between cross-sectional/survey and intervention designs, as well as between clinical and non-clinical samples. The SF-36 was used 27 times, the similar RAND-36 used 4 times, and several measures, including the Satisfaction with Life (SWL) scale 1–2 times. Extending our review from QoL to life satisfaction added 10 articles, with the SWL scale used slightly more, but otherwise similar patterns. CONCLUSION: We found a variety of measures, paralleling recent reviews of the larger clinical literature. We found no evidence of underlying conceptual models, and the most widely used measure, the SF-36, was developed primarily for clinical purposes from the Medical Outcomes Study (MOS). As described in Ware's (2000) update, the SF-36 was constructed to meet minimal psychometric standards, and the 8 health concepts represent those most frequently measured and believed most affected by disease and health conditions. Clearly the SF-36 did not emerge from a conceptual base, and despite widespread use, has no demonstrated validity or relevance for physical activity and health promotion research and practice. Our RESULTS confirm the lack of attention to QoL assessment, and highlight the need for further development of conceptually-based, psychometrically-sound, and relevant QoL measures in physical activity and health promotion.

PsycINFO

Promotion (chess)

10.1249/00005768-200605001-02444

Cite

Citations (5)

A pilot open trial evaluating the efficacy of low-dose aminopterin in the canine homologue of human atopic dermatitis

British Journal of Dermatology (2007)

Thierry Olivry Judy S. Paps Petra Bizikova Karen M. Murphy Hilary A. Jackson

Journal Article A pilot open trial evaluating the efficacy of low‐dose aminopterin in the canine homologue of human atopic dermatitis Get access T. Olivry, T. Olivry Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, U.S.A.Allergy Core, Center for Comparative Medicine and Translational Research, North Carolina State University, Raleigh, NC, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar J.S. Paps, J.S. Paps Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar P. Bizikova, P. Bizikova Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar K.M. Murphy, K.M. Murphy Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar H.A. Jackson, H.A. Jackson Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar J. Zebala J. Zebala Syntrix Biosystems, Auburn, WA, U.S.A. E‐mail: Thierry_Olivry@ncsu.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 157, Issue 5, 1 November 2007, Pages 1040–1042, https://doi.org/10.1111/j.1365-2133.2007.08133.x Published: 01 November 2007

10.1111/j.1365-2133.2007.08133.x

Cite

Citations (10)

Characterization of the inflammatory infiltrate during IgE‐mediated late phase reactions in the skin of normal and atopic dogs

Veterinary Dermatology (2001)

Thierry Olivry Stanley M. Dunston Karen M. Murphy Peter F. Moore

In canine and human atopic patients, the intracutaneous injection of offending allergens is followed by the development of both immediate and late‐phase reactions. The present study was performed to expand on the characterization and dynamics of inflammatory cell subsets during IgE‐mediated late‐phase reactions in canine skin. Three normal dogs and three Dermatophagoides farinae ‐allergic dogs were selected for this experiment. All dogs were challenged intradermally with mite allergen, purified anticanine IgE antibodies (positive control) or phosphate‐buffered saline (negative control). Skin biopsies were obtained before and 6, 12 and 24 h post‐injection. Sections were stained with metachromatic and eosinophil‐specific histological stains. Additionally, we used an immunohistochemical method with antibodies specific for canine leukocyte antigens. This study confirmed the occurrence of a late‐phase reaction in atopic skin following allergen challenge, and in normal and atopic canine skin after intradermal injection of IgE‐specific antibodies. Whereas early emigrating dermal cells were composed chiefly of neutrophil and activated eosinophil granulocytes, there was an influx of αβ T‐lymphocytes and dermal dendritic cells in later stages of the late‐phase reactions. Because IgE‐mediated late‐phase reactions resemble spontaneous atopic canine skin lesions, both at macroscopic and microscopic levels, we propose the use of similar challenges to study the anti‐inflammatory effects of anti‐allergic drugs in a pre‐clinical setting.

Intradermal injection

10.1046/j.1365-3164.2001.00230.x

Cite

Citations (60)

Exceptions to Outpatient Quality Measures for Coronary Artery Disease in Electronic Health Records

Annals of Internal Medicine (2011)

Karen S. Kmetik Michael O’Toole Heidi Bossley Carmen A. Brutico Gary S. Fischer

Physicians report outpatient quality measures from data in electronic health records to facilitate care improvement and qualify for incentive payments.To determine the frequency and validity of exceptions to quality measures and to test a system for classifying the reasons for these exceptions.Cross-sectional observational study.5 internal medicine or cardiology practices.47,075 patients with coronary artery disease between 2006 and 2007.Counts of adherence with and exceptions to 4 quality measures, on the basis of automatic reports of recommended drug therapy by computer software and separate manual reviews of electronic health records.3.5% of patients who had a drug recommended had an exception to the drug and were not prescribed it (95% CI, 3.4% to 3.7%). Clinicians did prescribe the recommended drug for many other patients with exceptions. In 538 randomly selected records, 92.6% (CI, 90.3% to 94.9%) of the exceptions reported automatically by computer software were also exceptions during manual review. Most medical exceptions were clinical contraindications, drug allergies, or drug intolerances. In 592 randomly selected records, an unreported exception or a drug prescription was found during manual review for 74.6% (CI, 71.1% to 78.1%) of patients for whom automatic reporting recorded a quality failure.The study used a convenience sample of practices, nonstandardized data extraction methods, only drug-related quality measures, and no financial incentives.Exceptions to recommended therapy occur infrequently and are usually valid. Physicians frequently prescribed drugs even when exceptions were present. Automated reports of quality failure often miss critical information.Agency for Healthcare Research and Quality.

Medical record

Electronic prescribing

10.7326/0003-4819-154-4-201102150-00003

Cite

Citations (16)

Quality of Life Survey--Version 2

PsycTESTS Dataset (2011)

Diane L. Gill Yu‐Kai Chang Karen M. Murphy Kathryn M. Speed Cara C. Hammond

10.1037/t09958-000

Cite

Citations (0)